ATE462724T1 - Mutierter androgenrezeptor, diesen exprimierende krebszellen, verfahren zur konstruktion davon und verwendung davon - Google Patents

Mutierter androgenrezeptor, diesen exprimierende krebszellen, verfahren zur konstruktion davon und verwendung davon

Info

Publication number
ATE462724T1
ATE462724T1 AT03730778T AT03730778T ATE462724T1 AT E462724 T1 ATE462724 T1 AT E462724T1 AT 03730778 T AT03730778 T AT 03730778T AT 03730778 T AT03730778 T AT 03730778T AT E462724 T1 ATE462724 T1 AT E462724T1
Authority
AT
Austria
Prior art keywords
androgen receptor
construction
cancer cells
cells expressing
androgen
Prior art date
Application number
AT03730778T
Other languages
English (en)
Inventor
Takahito Hara
Masami Kusaka
Junichi Miyazaki
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Application granted granted Critical
Publication of ATE462724T1 publication Critical patent/ATE462724T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
AT03730778T 2002-06-03 2003-06-02 Mutierter androgenrezeptor, diesen exprimierende krebszellen, verfahren zur konstruktion davon und verwendung davon ATE462724T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2002162206 2002-06-03
JP2002255612A JP4447826B2 (ja) 2002-06-03 2002-08-30 変異アンドロゲン受容体、それを発現する癌細胞、それらの作出方法およびそれらの用途
PCT/JP2003/006942 WO2003102188A1 (en) 2002-06-03 2003-06-02 Mutated androgen receptor, cancer cells expressing the same, method of constructing the same and use thereof

Publications (1)

Publication Number Publication Date
ATE462724T1 true ATE462724T1 (de) 2010-04-15

Family

ID=29714332

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03730778T ATE462724T1 (de) 2002-06-03 2003-06-02 Mutierter androgenrezeptor, diesen exprimierende krebszellen, verfahren zur konstruktion davon und verwendung davon

Country Status (7)

Country Link
US (1) US20050181462A1 (de)
EP (2) EP1550720B1 (de)
JP (1) JP4447826B2 (de)
AT (1) ATE462724T1 (de)
AU (1) AU2003241738A1 (de)
DE (1) DE60331934D1 (de)
WO (1) WO2003102188A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1553074B1 (de) 2002-08-12 2014-06-18 Takeda Pharmaceutical Company Limited Kondensiertes benzolderivat und verwendung
US8133724B2 (en) * 2008-09-17 2012-03-13 University Of Maryland, Baltimore Human androgen receptor alternative splice variants as biomarkers and therapeutic targets
US8841422B2 (en) 2008-09-17 2014-09-23 University Of Maryland, Baltimore Human androgen receptor alternative splice variants
WO2011040421A1 (ja) 2009-09-29 2011-04-07 武田薬品工業株式会社 スクリーニング方法
US10206911B2 (en) 2012-10-26 2019-02-19 Memorial Sloan-Kettering Cancer Center Androgen receptor variants and methods for making and using
CN117363621B (zh) * 2023-10-11 2024-09-13 南方医科大学南方医院 一种雄激素受体ar的n端体细胞基因突变体在构建抗肝癌药物筛选模型中的应用
CN117778322B (zh) * 2023-12-17 2025-02-07 苏州拓维生物技术有限公司 一种对恩杂鲁胺耐药的细胞系的筛选方法及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6994992B1 (en) * 1999-02-24 2006-02-07 Trustees Of Tufts College Androgen-induced suppressor of cell proliferation and uses thereof
GB0005689D0 (en) * 2000-03-09 2000-05-03 Schering Ag Crystal
US6291194B1 (en) * 2000-07-28 2001-09-18 Taneli Raivio Assay for determination of androgenic or anti-androgenic activity of a serum sample or a test compound
EP1466902A4 (de) * 2001-12-28 2005-11-09 Takeda Pharmaceutical Antagonisten des androgenrezeptors

Also Published As

Publication number Publication date
EP1550720A4 (de) 2006-07-26
EP1550720B1 (de) 2010-03-31
JP2004057180A (ja) 2004-02-26
AU2003241738A1 (en) 2003-12-19
DE60331934D1 (de) 2010-05-12
EP1550720A1 (de) 2005-07-06
JP4447826B2 (ja) 2010-04-07
WO2003102188A1 (en) 2003-12-11
US20050181462A1 (en) 2005-08-18
EP2090656A1 (de) 2009-08-19

Similar Documents

Publication Publication Date Title
DE60314500D1 (de) Diaminopyrimidine und deren verwendung als angiogenesehemmer
ATE526987T1 (de) Dr5-antikörper und deren verwendung
TW200631594A (en) Toll like receptor 3 antagonists, methods and uses
WO2005016967A3 (en) Modified human igf-1r antibodies
BRPI0507680A (pt) partìculas de fosfato de cálcio terapêuticas e métodos de fabricação e uso das mesmas
CY1112743T1 (el) Στερεοϊσομερως εμπλουτισμενες ενωσεις 3-αμινοκαρβονυλ δικυκλοεπτενο πυριμιδινοδιαμινης και οι χρησεις τους
CY1114443T1 (el) Απταμερη θεραπευτικα χρησιμα στην αντιμετωπιση των σχετικων με το συμπληρωμα διαταραχων
ATE313532T1 (de) Diaryl- und arylheteroarylharnstoffderivate als modulatoren des 5-ht2a-serotoninrezeptors, die sich zur prophylaxe und behandlung von damit im zusammenhang stehenden erkrankungen eignen
RS20080336A (en) Activin-actriia antagonists and uses for promoting bone growth
DE502004012162D1 (de) Elektrosterisch stabilisierte wässrige polyurethan-harze, verfahren zu ihrer herstellung und deren verwendung
WO2004098377A3 (en) Methods and compositions for diagnosis and therapy of parkin-associated disorders
ATE517094T1 (de) Verfahren zur herstellung von medetomidin und seinen salzen
ATE325789T1 (de) Aminocyclohexylether-verbindungen und deren verwendung
ATE462724T1 (de) Mutierter androgenrezeptor, diesen exprimierende krebszellen, verfahren zur konstruktion davon und verwendung davon
PT1899334E (pt) Compostos de naftiridina
ATE411981T1 (de) Tetrahydrocarbazolderivate und deren pharmazeutische verwendung
CY1108809T1 (el) Μεθοδοι κατασκευης 6-[(4.5-διϋδρο-1η-ιμιδαζολ-2-υλ)αμινο-]-7-μεθυλ-1η-βενζιμιδαζολο-4-kapboniτριλιου και προτιμωμενη μορφη αλατος αυτου
WO2005058251A3 (en) Hla-dr-specific antibodies, compositions and methods
EP1749298B8 (de) Prozess zur herstellung eines stanzers für einen mehrwertigen rom-datenträger, herstellungsvorrichtung dafür und resultierender datenträger
AU2003294324A1 (en) Compositions and methods for the treatment of cancer, screening of putative anti-cancer compounds, and assessing cancer progression
WO2004113574A3 (en) Methods for disease screening
WO2005089294A3 (en) Synthesis of indenoisoquinoliniums and methods of use
ATE446299T1 (de) Verfahren zur herstellung von 7-ethyl-10- hydroxycamptothecin
MXPA05009428A (es) Composiciones y metodos para prevenir y tratar enfermedades relacionadas con endotoxinas.
DE602005015329D1 (de) Rutheniumkomplexe zur krebsbehandlung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties